Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 4 | 6 | — | — | 10 |
Sclerosis | D012598 | — | — | — | 3 | 6 | — | — | 9 |
Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 3 | 5 | — | — | 8 |
Disease progression | D018450 | — | — | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 2 | — | — | — | 2 |
Lupus nephritis | D008181 | EFO_0005761 | — | — | 1 | — | — | — | 1 |
Nephritis | D009393 | — | N05 | — | 1 | — | — | — | 1 |
Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | 1 | — | — | — | 1 |
Huntington disease | D006816 | Orphanet_399 | G10 | — | 1 | — | — | — | 1 |
Arthritis | D001168 | EFO_0005856 | M05-M14 | — | 1 | — | — | — | 1 |
Lupus erythematosus panniculitis | D015435 | — | L93.2 | — | 1 | — | — | — | 1 |
Crohn disease | D003424 | EFO_0000384 | K50 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Pharmacological phenomena | D000069437 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Laquinimod |
INN | laquinimod |
Description | Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease.
|
Classification | Small molecule |
Drug class | immunomodulators |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1 |
PDB | — |
CAS-ID | 248282-07-7 |
RxCUI | — |
ChEMBL ID | CHEMBL66092 |
ChEBI ID | — |
PubChem CID | 216469 |
DrugBank | — |
UNII ID | 908SY76S4G (ChemIDplus, GSRS) |